Drug Profile
ZSP 1603
Alternative Names: ZSP-1603Latest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator Guangdong Zhongsheng Pharmaceutical
- Developer Guangdong Raynovent Biotech; Guangdong Zhongsheng Pharmaceutical
- Class Antifibrotics; Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Idiopathic pulmonary fibrosis
- Phase I Non-alcoholic steatohepatitis
- No development reported Solid tumours
Most Recent Events
- 29 Nov 2022 Phase-I clinical trials in Non-alcoholic steatohepatitis in China (unspecified route) (Guangdong Raynovent Biotech pipeline; November 2022)
- 21 Oct 2021 Phase-I/II clinical trials in Idiopathic pulmonary fibrosis in China (PO) (NCT05119972)
- 01 Oct 2021 Phase-I development in Idiopathic pulmonary fibrosis is ongoing in China (NCT05119972)